CTLA4 and hypophysitis: Anti-CTLA-4 therapies mobilize naïve T cells, which initiate immune responses against the pituitary gland (hypophysitis), leading to immune cell infiltration and glandular inflammation, further causing structural damage and symptoms such as headaches, visual impairment, and hormone deficiencies [15].